Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Tax Provisions: 2014-2025

Historic Tax Provisions for Enanta Pharmaceuticals (ENTA) over the last 12 years, with Sep 2025 value amounting to -$80,000.

  • Enanta Pharmaceuticals' Tax Provisions rose 85.61% to -$80,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.8 million, marking a year-over-year increase of 8.47%. This contributed to the annual value of -$1.8 million for FY2025, which is 8.47% up from last year.
  • According to the latest figures from Q3 2025, Enanta Pharmaceuticals' Tax Provisions is -$80,000, which was down 375.86% from $29,000 recorded in Q2 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Tax Provisions ranged from a high of $7.1 million in Q1 2021 and a low of -$9.4 million during Q2 2021.
  • Moreover, its 3-year median value for Tax Provisions was -$395,000 (2024), whereas its average is -$77,545.
  • Examining YoY changes over the last 5 years, Enanta Pharmaceuticals' Tax Provisions showed a top increase of 1,044.30% in 2023 and a maximum decrease of 70,400.00% in 2023.
  • Over the past 5 years, Enanta Pharmaceuticals' Tax Provisions (Quarterly) stood at -$36,000 in 2021, then increased by 5.56% to -$34,000 in 2022, then tumbled by 1,729.41% to -$622,000 in 2023, then skyrocketed by 33.12% to -$416,000 in 2024, then surged by 85.61% to -$80,000 in 2025.
  • Its Tax Provisions was -$80,000 in Q3 2025, compared to $29,000 in Q2 2025 and -$1.3 million in Q1 2025.